MARKET

EXEL

EXEL

Exelixis Inc
NASDAQ
16.41
+0.06
+0.37%
After Hours: 16.41 0 0.00% 16:00 10/04 EDT
OPEN
16.55
PREV CLOSE
16.35
HIGH
16.77
LOW
16.24
VOLUME
3.22M
TURNOVER
0
52 WEEK HIGH
23.40
52 WEEK LOW
15.50
MARKET CAP
5.28B
P/E (TTM)
19.47
1D
5D
1M
3M
1Y
5Y
Exelixis expands cancer clinical trial collaboration & supply pact with Bristol-Myers
Exelixis (NASDAQ:EXEL) on Tuesday said it would include the use of...
Seekingalpha · 20h ago
Exelixis Expands Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb To Include Fixed-Dose Combination Of Nivolumab And Relatlimab In Combination With XL092 In Phase 1b STELLAR-002 Trial
Agreement enables evaluation of XL092 in combination with an additional immune checkpoint inhibitor — ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (NASDAQ:EXEL) today announced the expansion of its June 2021
Benzinga · 21h ago
Exelixis (NASDAQ:EXEL) investors are sitting on a loss of 39% if they invested five years ago
Ideally, your overall portfolio should beat the market average. But in any portfolio, there will be mixed results...
Simply Wall St. · 09/14 16:41
Exelixis' XL092/ Atezolizumab Shows Encouraging Efficacy, Safety In Heavily Pretreated Cancer Patients
Benzinga · 09/12 13:14
BRIEF-Exelixis Announces Dose-Escalation Results From The Phase 1 Stellar-001 Trial
BRIEF-Exelixis Announces Dose-Escalation Results From The Phase 1 Stellar-001 Trial
Reuters · 09/10 09:15
Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022
ALAMEDA, Calif., September 10, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced results from the dose-escalation stage of STELLAR-001, an ongoing phase 1b trial evaluating XL092 as a single-agent and in combination with atezolizumab in patients with loc...
Business Wire · 09/10 07:00
Exelixis Announces Detailed Results From Late-Stage Cabometyx Combo Trial In Kidney Cancer
Benzinga · 09/08 17:48
Exelixis (EXEL) Reports Positive Cabometyx Combo Study Results
Exelixis (EXEL) announces positive detailed results on the triplet combination study of Cabometyx, Opdivo and Yervoy.
Zacks · 09/08 15:55
More
About EXEL
Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Webull offers kinds of Exelixis, Inc. stock information, including NASDAQ:EXEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXEL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EXEL stock methods without spending real money on the virtual paper trading platform.